Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. Clinicians face the difficult challenge of patient prioritization, identifying which patients to admit and how to effectively triage them within emergency room and hospital settings, and which patients can safely get the care they need at home, in isolation.
Accurately predicting which COVID-19 patients are at risk of severe disease and deterioration, as well as personalized management of critically ill patients, remains challenging due to the heterogeneous nature of the virus and the limitations of available diagnostic tools. Today, however, novel host immune response technologies are yielding clues on how to best triage COVID-19 patients, showing promise in changing the paradigm in acute care patient management.
Please join 360Dx and MeMed for a discussion with a panel of international experts on recent advances in the technologies used to probe the host immune response to infections, including COVID-19. Panelists will share new research and insights from their experiences on how predictive biomarkers – and the actionable information they provide – can potentially be used in clinical practice to enable more accurate, rapid diagnoses and timely interventions that can help reduce ICU admissions, the need for ventilation and, ultimately, mortality.
This discussion will cover:
● Recent prospective data on the potential utility of a host immune signature, which combines three biomarkers (TRAIL, IP-10, CRP), as a valuable resource for predicting disease severity and progression;
● How utilizing IP-10 as a biomarker in real-world settings can aid in monitoring inflammatory status and personalizing treatment strategies for patients with severe COVID-19;
● The applications of host immune response technologies in easing the burdens on healthcare systems presented by COVID-19 as well as future pandemics.